ClinicalTrials.gg
RecruitingNCT06436053Updated Jul 9, 2026

Acute Response to Left Bundle Branch Area Pacing With SyncAV

An observational study in Heart Failure, sponsored by Abbott Medical Devices. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Abbott Medical Devices (part of Abbott) · Observational

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 120 studies in Heart Failure by Abbott — 6 open to participants now, 9 under way, none of them phase 3. Heart Failure · Abbott.

Planned enrollment
32nd of 45
50 · median 154
Started
2024
with 1 other
Observational
45 of 120
4 open now
Registered
115th of 120
by date

Among the 120 studies in Heart Failure by Abbott, this one is the 32nd largest by planned enrollment of the 45 observational ones that give a count, is one of 2 that started in 2024, is one of 45 observational ones, and was the 115th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 120 studies in Heart Failure by Abbott are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Heart Failure by Abbott, or all of them as a file.
02

Study summary

This clinical investigation is a prospective, single-arm, post-market, non-randomized, single-center study designed to evaluate the effectiveness of the SyncAV CRT dynamic atrioventricular (AV) delay feature when used with left bundle branch area pacing (LBBAP).

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with approved indication for dual-chamber pacing or cardiac resynchronization therapy, with documented left bundle branch block or intraventricular conduction delay, long QRS duration, and intact AV conduction will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is 18 years of age and willing to comply with the study requirements
  2. Patients with approved indication for dual-chamber pacing or cardiac resynchronization therapy and scheduled to be implanted with an Abbott pacing system
  3. Patient has documented left bundle branch block (LBBB) or intraventricular conduction delay (IVCD)
  4. Patient has an intrinsic QRS duration ≥ 130 ms
  5. Patient has intact AV conduction with PR interval ≤ 250 ms

Exclusion criteria

Exclusion Criteria:

  1. Patient has a resting ventricular rate > 100 bpm
  2. Patient has AV Block (2nd or 3rd degree)
  3. Patient has documented persistent atrial tachycardia or atrial fibrillation
  4. Patient has had a recent myocardial infarction, ablation, electrolyte imbalance, or any condition within the last 90 days that would contraindicate for pacing device programming changes in the opinion of the investigator
  5. Patient is currently participating in another clinical investigation
  6. Patient is pregnant or nursing
  7. Patient has other medical, anatomic, comorbid, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
  8. Patient does not have legal authority
  9. Patient is unable to read or write
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • LBBAP with SyncAV

    Device: LBBAP with SyncAV

Interventions

  • DeviceLBBAP with SyncAV

    Acute changes in surface ECG QRS duration resulting from left bundle branch area pacing using various pacing configurations will be evaluated.

06

What researchers measure

Primary outcomes

  1. QRS duration

    Acute change in surface ECG QRS duration resulting from left bundle branch area pacing with optimized SyncAV, relative to intrinsic atrioventricular conduction.

    Time frame: During the intervention/procedure/surgery

Secondary outcomes

  1. LV hemodynamics

    Acute change in left ventricular hemodynamics (i.e., maximum rise in pressure) resulting from left bundle branch area pacing with optimized SyncAV, relative to intrinsic atrioventricular conduction.

    Time frame: During the intervention/procedure/surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 183 industry-sponsored observational studies under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's planned 31 months is close to that.

Counting every sponsor, half of 981 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
May 30, 2024
StartActual
May 15, 2024
Primary completionEst.
Dec 15, 2026
CompletionEst.
Jul 15, 2027
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06436053
Responsible party
Sponsor
First posted
May 30, 2024
Start date
May 15, 2024
Primary completion
Dec 15, 2026 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Jul 9, 2026

Study contacts

Nima Badie, PhD
Contact
nima.badie@abbott.com
408-702-8604

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion